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ABSTRACT
Background Most patients with advanced melanomas
relapse after checkpoint blockade therapy. Thus,
immunotherapies are needed that can be applied safely
early, in the adjuvant setting. Seviprotimut-L is a vaccine
containing human melanoma antigens, plus alum. To
assess the efficacy of seviprotimut-L, the Melanoma
Antigen Vaccine Immunotherapy Study (MAVIS) was
initiated as a three-part multicenter, double-blind, placebo-
controlled phase III trial. Results from part B1 are reported
here.
Methods Patients with AJCC V.7 stage IIB-III cutaneous
melanoma after resection were randomized 2:1, with stage
stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or
placebo. Recurrence-free survival (RFS) was the primary
endpoint. For an hypothesized HR of 0.625, one-sided
alpha of 0.10, and power 80%, target enrollment was 325
patients.
Results For randomized patients (n=347), arms were
well-balanced, and treatment-emergent adverse events
were similar for seviprotimut-L and placebo. For the
primary intent-to-treat endpoint of RFS, the estimated
HR was 0.881 (95% CI: 0.629 to 1.233), with stratified
logrank p=0.46. However, estimated HRs were not
uniform over the stage randomized strata, with HRs (95%
CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37
to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI:
0.72 to 1.97), respectively. In the stage IIB/IIC stratum,
the effect on RFS was greatest for patients <60 years
old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with
ulcerated primary melanomas (HR=0.493 (95% CI: 0.255
to 0.952)).

Conclusions Seviprotimut-L is very well tolerated.
Exploratory efficacy model estimation supports further
study in stage IIB/IIC patients, especially younger patients
and those with ulcerated melanomas.
Trial registration number NCT01546571.

INTRODUCTION
Patients with resected stage IIB, IIC, or III
melanoma are at high risk for recurrence and
death after surgery. The only adjuvant therapy
approved for stage IIB-IIC melanoma is high
dose interferon, which prolongs recurrence-
free survival (RFS) but has little or no proven
impact on overall survival.1 Current National
Comprehensive Cancer Network (NCCN)
guidelines do not recommend interferon
therapy for stage IIB-
IIC melanoma.2 For
stage III melanoma, adjuvant therapies
approved by the United States Food and Drug
Administration (U.S. FDA) include blockade
of Programmed cell Death protein 1 (PD-1)
with nivolumab or pembrolizumab, blockade
of cytotoxic T-lymphocyte-Associated Protein
4 (CTLA-
4) with ipilimumab, and inhibition of v-raf murine sarcoma viral oncogene
homolog B1 (BRAF) and mitogen-activated
protein kinase kinase (MEK) with dabrafenib
and trametinib, respectively. However, for
those with BRAF-wild type melanomas and

Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272

1

J Immunother Cancer: first published as 10.1136/jitc-2021-003272 on 1 October 2021. Downloaded from http://jitc.bmj.com/ on November 15, 2021 by guest. Protected by copyright.

Multicenter, double-blind, placebo-
controlled trial of seviprotimut-L
polyvalent melanoma vaccine in
patients with post-resection melanoma
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METHODS
Part B1 of the MAVIS trial was a prospective double-
blind, randomized, placebo-controlled phase III clinical
trial. The investigators and subjects were blinded as to
2

treatment assignment; the placebo injections appeared
identical to the seviprotimut-L injections.
Participant eligibility
Participants 18–80 years of age were eligible if they had
histologically confirmed AJCC Stage IIB, IIC, or III cutaneous melanoma (AJCC V.7) rendered clinically free of
disease by surgery within 90 days. Patients with positive
sentinel nodes were required to have a complete lymphadenectomy, except for patients on the Multicenter Selective Lymphadenectomy Trial II (MSLT-II, NCT00297895)8
who were randomized in that study to the observation
arm. Also required were: Eastern Cooperative Oncology
Group (ECOG) performance status 0–1, ability and willingness to give informed consent, normal organ function,
and absence of major autoimmune disorders. Participants
were required either to have known BRAF V600 mutation
status or archival tissue available to test for BRAF mutation
status. Participants were excluded for pregnancy, prior
melanoma treatment other than surgery, regional radiation therapy or adjuvant interferon alfa-2b within 1 week
of starting treatment, concurrent cancer therapy, concurrent immune therapy, chronic use of systemic corticosteroids, prior splenectomy, known HIV positivity, allergy to
alum, or autoimmune disorders requiring therapy or with
visceral involvement, or another malignancy within the
prior 5 years (except adequately treated in situ squamous
cell carcinoma, basal cell carcinoma, stage I or IIA melanoma, or carcinoma in situ of the cervix).
Vaccine components and treatment regimen
Seviprotimut-
L is a polyvalent suspension melanoma
cancer vaccine that includes multiple melanoma antigens
shed from three human melanoma cell lines as the active
pharmaceutical ingredient (API). These three lines are
SFHM2, SFHM4, and SFHM8 and have previously been
referred to as M20, M14, and SK-
Mel-
28, respectively:
M20 was established from a metastatic melanoma9; M14
was established from an amelanotic metastatic lesion of
a 33-year-old man and is BRAF-mutant (V600E)10; and
SK-
Mel-
28 was originally established from an axillary
lymph node of a 51-year-old man and is BRAF-mutant
(V600E), with wild-type Neuroblastoma RAS viral oncolog
gene homolog (NRAS).11–13 Additional information
about each has been reported previously.14 For vaccine
production, the material shed into serum-
free culture
medium by the cells was collected, pooled, concentrated,
treated with non-ionic detergent Nonidet P-40 to disaggregate antigens, and ultracentrifuged to remove particulate matter. The supernatant was filter-sterilized, adjusted
to the appropriate protein concentration, and bound
to alum as an adjuvant. Seviprotimut-L is thus partially
purified, being made of soluble shed antigens, to exclude
the bulk of unrelated cellular material that is present in
the cell cytoplasm or nucleus. The Drug Product was a
nominal 0.8 mL suspension containing 0.05 mg/mL
API with 1 mg/mL aluminum in aluminum hydroxide
suspensions in 4 mM phosphate-buffered saline and 0.9%
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low volume lymph node metastases, the risk: benefit
ratio may not favor treatment with checkpoint blockade
therapy. In addition, a significant portion of patients still
recur despite approved adjuvant therapies. Thus, there is
a need for effective systemic adjuvant therapy for patients
with stage IIB-IIC melanoma and for subsets of patients
with stage III melanoma.
Cancer vaccines offer promise to prevent melanoma
recurrence by enhancing melanoma-
specific immune
responses. However, no cancer vaccine has yet proven
effective for prolonging RFS or survival after melanoma resection. Seviprotimut-
L (formerly POL-
103A)
was developed based on data from a prototype polyvalent melanoma vaccine comprised of shed antigens
from four melanoma cell lines, administered with
alum or interleukin (IL)-
2 liposomes. That prototype
vaccine contained multiple shared melanoma antigens,
including MAGE-A3, MelanA, gp100, tyrosinase, melanocortin 1 receptor and tyrosinase-related protein 23 4 and
it induced antibody responses that were associated with
improved clinical outcome.5 It also induced CD8 T cell
responses to peptides restricted by Class I Major Histocompatability Complex (MHC) molecules.3 6 Over 600
patients were enrolled on trials testing versions of the
prototype vaccine, with no safety concerns. In a small
double-blind, placebo-controlled trial of a version of the
prototype vaccine in patients with resected high-risk stage
III melanoma (n=38), RFS of the melanoma vaccine-
treated patients was over twice as long as that of placebo
vaccine-treated patients (p=0.03).7
The polyvalent vaccine has been reformulated as
seviprotimut-
L, prepared from antigens shed by three
human melanoma cell lines administered with alum. A
three-part, Phase III clinical trial program, termed Melanoma Antigen Vaccine Immunotherapy Study (MAVIS)
was initiated. The trial program was originally designed
to include two separate clinical trials: Part A to select
between two dose levels of seviprotimut-L based on safety
and immunogenicity, and Part B to evaluate safety and
efficacy of the selected dose. A dose of 40 mcg was selected
in Part A based on safety and induction of serum antibody to melanoma antigens. In the course of conducting
Part B (in 2016), the sponsor decided to split Part B into
two parts—Part B1 to identify a signal of clinical efficacy,
prior to initiating Part B2 which would be the definitive
evaluation of clinical efficacy. Thus, Part B1 of MAVIS
was a multicenter, double-blind, placebo-controlled trial
to assess the efficacy of seviprotimut-L at that dose, with
the primary endpoint of RFS in patients at high risk of
recurrence after definitive surgical resection. The present
manuscript reports the final clinical outcome data from
Part B1 of the MAVIS trial.

Open access

Study design, power analysis, and objectives
Part B1 of MAVIS was a two-arm, multicenter, randomized, double-blind, placebo-controlled trial with a goal
of randomizing at least 325 patients in a 2:1 ratio for
probability of assignment to the experimental arm.
The primary endpoint was RFS. Secondary objectives
included: (a) to assess the efficacy of treatment with seviprotimut-L compared with placebo with respect to overall
survival (OS); and (b) to verify the safety and tolerability
of seviprotimut-L at the dose selected for Part B. As Part
B1 was intended to identify a signal of clinical efficacy
prior to embarking on the definitive Part B2, the p value
was set at 0.2, and hence fewer events/patients were
required. For assessment of RFS, the study was powered
with hypothesized HR of 0.625, one-sided alpha of 0.10,
and power 80%, with target assessment after 126 RFS
events, based on the possibility of a delayed effect due to
immunotherapy.15
Eligible patients received either seviprotimut-L at the
dose determined from Part A (40 µg) or placebo. Patients
were stratified at randomization according to their stage
of disease at enrollment (IIB/IIC vs IIIA vs IIIB/IIIC) to
increase the likelihood of intended distribution between
the study arms. Patients were treated every 2 weeks×4, then
monthly×4, then every 3 months through month 24 (ie,
weeks 0, 2, 4, 6, 8, then months 3, 4, 5, 6, 9, 12, 15, 18, 21,
24). Each subject was treated unless one of the following
occurred: development of recurrent disease that did not
meet the criteria for continued dosing, death, subject
withdrawal, or study termination, whichever came first.
Patients were followed for recurrence and survival. They
were not routinely unblinded following recurrence or the
end of treatment except to allow the subject to pursue
other treatment options.
Toxicity and dose-limiting toxicities
Safety was assessed throughout the study. Adverse events
(AEs) were reported from randomization through 30 days
after the last study drug administration and were graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events V.4. Relatedness
of AEs to study drug was reported using WHO definitions:
Probable, Possible, and Unlikely.
An adverse event or suspected adverse reaction was
considered ‘serious’ (SAE) if, in the view of either the
investigator or sponsor, it resulted in any of the following
outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial
Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272

disruption of the ability to conduct normal life functions,
or a congenital anomaly/birth defect. Other events
would be considered serious when, based on appropriate
medical judgment, they may jeopardize the patient or
subject and may require medical or surgical intervention
to prevent one of the outcomes listed in this definition.
Clinical outcome
The date of recurrence was defined as the earliest date
a recurrence was suspected, with biopsy confirmation,
except in rare cases where biopsies were not clinically
appropriate (eg, brain metastases). Recurrence events
included appearance of locoregional metastasis, distant
metastasis, or a new primary melanoma. Since the validation of recurrence primarily relied on biopsies, there was
no central reading of CT scans to confirm recurrence.
Recurrence assessments were to be based on cross-
sectional imaging every 6 months. Serum lactate dehydrogenase (LDH) was also monitored every 3 months, and
LDH elevations ≥1.5×upper limit of normal were followed
up with radiological scans, provided there were no other
obvious medical reasons for the elevated LDH.
Statistical methods
The primary analysis outcome is RFS time, computed as
the number of days from the date of randomization to the
earliest of recurrence or death. Patients without recurrence or death were censored at the date last assessed for
recurrence. All analyses are based on the intent-to-treat
(ITT) principle. The primary analysis is the stratified
logrank test, with the stage at randomization as stratifier.
HR estimates and their 95% CIs are from proportional
hazard regression models using stage at randomization
as stratifier as applicable. Sensitivity and exploratory
analyses included effect modification assessment for the
existence of heterogeneity of RFS effect estimated across
subsets defined by baseline attributes and is based on a
proportional hazard regression with terms for baseline
attribute, arm, and one or more terms as necessary for
the interaction between baseline attribute and arm. In
effect modification assessments, an interaction p value in
the neighborhood of 0.1 or less is regarded as evidence of
effect modification (this interaction p value is to be interpreted as a measure of the contribution of interaction
to the fit of the model). Graphs show the Kaplan-Meier
estimators of the time-to-event distributions. Beyond the
primary analysis, all analyses are presented as exploratory
with arm effect estimates and 95% CIs.

RESULTS
Patients
Three hundred and forty-
seven patients at 65 centers
in the USA and Canada were randomized January 2015
through August 2016. Arms were well-balanced (table 1).
About one-third of patients had a BRAF mutation. Only
5% had had any prior melanoma therapy other than
surgery, and these were primarily radiotherapy. None had
3
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sodium chloride, at pH 6.8. The Drug Product was packaged in Type I glass vials with Teflon-coated bromobutyl
stoppers and was stored at 2°C–8°C (refrigerated) until
use. The vaccine was used as is and required no reconstitution after warming to room temperature. The doses
tested in Part A had included 40 mcg and 100 mcg, where
40 mcg protein had been the dose in the small randomied
trial of a similar vaccine preparation.7
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Seviprotimut-L

Placebo

N

230

117

Age: median (range)

58 (18, 80)

56 (26, 80)

Sex: % female

42

44

Race: % white

99

100

 Any

5.2

4.3

 Radiotherapy

4.3

4.3

 Extremities

35

37

 Head and neck

26

21

 Trunk

37

41

 Other

2.6

0.9

Ethnicity: % Hispanic or Latino

3

3.4

ECOG performance status 0 (%)

86

86

Completed lymphadenectomy (%)

64

64

Median Breslow depth (mm)

2.8

3

 T0 or TX

4.8

5.1

 T1–T2a

29

27

 T2b–T4a

48

55

 T4b

18

17

 N0

32

32

 N1a

36

30

 N1b–N2b

19

23

 N2c/N3

13

15

 IIB/IIC

32

32

 IIIA

30

29

 IIIB/IIIC

38

39

BRAF mutant* (%)

35

33

Prior melanoma therapy (%)

Tumor location (%)

T staging (%)

N staging (%)

Summary AJCC stage (V.7, %)

*BRAF mutation status known for 93%, 96%, and 94% of patients
receiving vaccine, placebo, or total. Values shown above are
percentages of all.

prior immunotherapy, small molecule targeted agents,
antibody therapy, or anti-
angiogenic therapy. Patients
on the MSLT-II trial were allowed to enroll only after
amendment 3. Only one, on the observation arm, is documented to be enrolled also on MSLT-II. The data in this
manuscript were collected after datalock in January 2020,
and findings were provided to the coauthors in April
2020, after which analyses and statistical review led to the
present manuscript.
Adverse events and safety assessment
Over 95% of patients on both study arms had one or
more treatment-
emergent AE’s, and 71% had one or
more treatment-related AEs (TRAEs), all of which are
detailed in online supplemental table 1. The vast majority
4

were grade 1, with fewer grade 2 TRAEs and very few
grade 3 TRAEs. The TRAEs observed in 3% or more of
patients overall, listed in table 2, included local symptoms at the injection sites (erythema, pruritus, pain,
swelling, bruising, induration, and rash) and systemic
symptoms (fatigue, headache, nausea, pruritus, myalgia,
rash, influenza-like illness symptoms, and diarrhea). The
incidence of those AEs and associated AE categories were
similar between the two study arms. The only AE with
slightly higher incidence in the vaccine arm was injection site pruritus (20% vs 12%). There were no grade 4–5
TRAEs and no treatment-related SAEs (table 3). Only one
patient discontinued therapy for a TRAE: a macular rash
on the vaccine arm. Sixty-two per cent completed all 24
months of therapy; 32% discontinued early for disease
progression (table 3). Evidence of autoimmune disease in
the eyes and skin was assessed every 6 months. Evidence
of ocular autoimmune disease was reported only in one
participant at month 12 on the vaccine arm and in none
on the placebo arm. Evidence of autoimmune disease in
the skin was observed in small numbers on both vaccine
and placebo arms, with no evidence of a treatment-related
effect (online supplemental table 2).
RFS
The primary analysis in this report is based on data with
149 RFS events at the data cut-off date. For this primary
analysis, the estimated HR is 0.881 (95% CI: 0.629 to
1.233), with p=0.460. Kaplan-Meier estimates are shown
in figure 1A. Thus, the trial failed to meet the planned
primary statistical criterion. However, there was notable
quantitative heterogeneity in HR estimates across stage-
specific randomization strata. For stages IIB/IIC (n=111),
IIIA (n=103), IIIB/IIIC (n=133), respectively, these HR
estimates (and 95% CIs) are 0.666 (95% CI: 0.373 to 1.189),
0.721 (95% CI: 0.347 to 1.496), and 1.191 (95% CI: 0.720
to 1.970). Figure 1B shows the Kaplan-Meier estimates
by stage and arm. The sites of metastasis were defined
as locoregional or distant for 137 patients, including 47,
24, and 66 for stages IIB/IIC, IIIA, IIIB/C, respectively:
of these, relapses were distant in 26 (55%), 10 (42%),
and 37 (56%), respectively (data not shown). Patients
were stratified and randomized for enrollment on this
trial based on AJCC V.7 staging. AJCC V.8 classifies stage
IIB and IIC patients the same as V.7; so, analyses of this
subset are the same using AJCC V.8. There were changes
for AJCC V.8 in substaging stage III patients, but reanalysis of outcomes in stage III patients is inconsistent with
the randomization stratification. The finding of a potentially clinically meaningful stage IIB/IIC point estimate
and the consistent and distinct separation between arms
for stage IIB/IIC as seen in the Kaplan-Meier estimates
(figure 1B) led to further exploration of the stage IIB/
IIC patients with the intent to inform planning the Part
B2 phase III trial. Additional factors explored as potential
effect modifiers within the stage IIB/IIC group included
age, sex, tumor location, thickness, ulceration, BRAF
mutation status, and LDH. Suggestion of the existence of
Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272
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Table 1 Enrollment, demographics, and clinical features
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****
Any
Any
Any
Any
Any
Injection site erythema
Fatigue
Injection site pruritus
Injection site pain
Headache
Injection site swelling
Nausea
Injection site bruising
Pruritus
Myalgia
Rash
Influenza-like illness
Injection site induration
Diarrhea
Injection site rash

Participant maximum grade

Skin/subcutaneous tissue

Nervous system

Gastrointestinal

Musculoskeletal/connective tissue

General and administration site

General and administration site

General and administration site

General and administration site

Nervous system

General and administration site

Gastrointestinal

General and administration site

Skin/subcutaneous tissue

Musculoskeletal/connective tissue

Skin/subcutaneous tissue

General and administration site

General and administration site

Gastrointestinal

General and administration site

AE

8

5

9

6

7

9

11

12

13

15

13

29

44

34

72

16

23

19

27

130

G1

3

2

1

2

2

2

8

1

4

1

2

6

14

G2

1

1

1

3

G3

N=230
Seviprotimut-L
G4

3

6

3

3

4

4

5

6

4

6

12

12

13

23

48

11

9

16

17

68

G1

2

1

1

1

1

3

1

1

4

5

11

11

12

9

11

13

16

18

17

21

25

41

57

57

120

27

32

35

44

198

3

2

1

2

2

2

3

3

11

1

5

2

2

10

19

G2

N=347
Total

G2 G3 G4 G1

N=117
Placebo

Treatment-related adverse events (AEs) observed in 3% or more of patients

1

1

1

3

G3

G4

11 (3)

11 (3)

12 (3)

12 (3)

14 (4)

14 (4)

18 (5)

18 (5)

19 (5)

21 (6)

28 (8)

44 (13)

60 (17)

68 (20)

121 (35)

32 (9)

34 (10)

38 (11)

57 (16)

217 (63)

245 (71)

G1—G3

# (%) any
grade

3

2

4

4

3

4

6

5

6

7

7

13

20

18

32

9

10

10

16

63

G1—G3

% any grade
Seviprotimut-L

3

5

3

3

5

4

4

5

4

5

10

11

12

22

41

10

9

14

18

62

G1—G3

% any grade
Placebo
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General and administration site

Category

Table 2

Open access

Open access

Seviprotimut-L Placebo Total
N

230

117

347

AEs

96%

97%

96%

Grade 3 AEs

12%

9%

11%

Grade 4–5 AEs

0%

0%

0%

Treatment-related AEs
(TRAEs)

70%

73%

71%

Treatment-related serious
AEs

0%

0%

0%

AEs leading to d/c study
drug*

0.9%

0.9%

0.9%

TRAEs leading to d/c study 0.4%
drug

0%

0.3%

Completed 24 months of
treatment

61.3%

63.2%

62.0%

D/C early for progressive
disease

31.7%

31.6%

31.7%

D/C early for withdrawal of 3.9%
consent

1.7%

3.2%

D/C early for TRAE

0.4%

0%

0.3%

Lost to follow-up,
pregnancy, other cancer

2.6%

3.4%

2.9%

Total

100%

100%

100%

*AEs leading to discontinuation (d/c) of study drug included one
TRAE (macular rash) on the vaccine arm, and development of
adenocarcinoma of the colon on the vaccine arm and squamous
cell carcinoma of the larynx on the placebo arm.

an effect modification was found for age as <60 versus ≥60
years and for the presence of ulceration, with interaction
p values of 0.0581 and 0.1136, respectively. The findings
are illustrated for age in figure 1C,D for the ITT data set
and stage IIB/C group, respectively.
Findings regarding effect modification by the presence
of ulceration and age for the stage IIB/C stratum are illustrated in figure 2. For this stratum, the HR for ulcerated
melanomas was 0.493 (95% CI: 0.255 to 0.952), as shown
in figure 2A. The interactions between age (≤60 and >60
years) and ulceration for the stage IIB/IIC stratum are
further detailed in figure 2B,C. For those under age 60
with ulcerated melanomas, specifically, the HR was 0.213
(95% CI: 0.065 to 0.702) favoring the vaccine arm.
Overall survival
OS was a secondary endpoint. With 41 deaths, there is
reduced sensitivity for detecting treatment effects on OS;
however, by ITT analysis, the estimated HR favors the
vaccine arm (HR=0.64 (95% CI: 0.34 to 1.18), figure 3A).
Also, the ranking across disease stages for OS is similar to
the quantitative relationships in the RFS analyses. Analysis of subgroups based on planned stratification by stage
(figure 3B) replicated the RFS trend, with evidence of a
strong HR effect in Stage IIB/IIC patients (n=111, HR
0.338 (95% CI: 0.117 to 0.975), figure 3B,D). Also, the
6

survival HR for the 191 patients <60 years old was 0.412
(95% CI: 0.167 to 1.014, figure 3C,D), while for the 156
patients ≥60 years old, the HR was 0.91 (95% CI: 0.38 to
2.17, figure 3C,D). For stage IIB/IIC stratum, the survival
HR for the 52 patients <60 years old was 0.216 (95% CI:
0.039 to 1.19), and for the 59 patients ≥60 years old, the
HR was 0.49 (95% CI: 0.12 to 1.98, figure 3E). The survival
HR for 160 patients with ulcerated primary melanomas
was 0.51 (95% CI: 0.22 to 1.16), and for the stage IIB/
IIC stratum, the survival HR for 84 patients with ulcerated
melanomas was 0.345 (95% CI: 0.10 to 1.14; not shown).
DISCUSSION
Seviprotimut-L treatment was very well tolerated, with no
SAEs and without a clear signal for increases in TRAEs
compared with placebo injections. Part B1 of the MAVIS
trial was designed to obtain preliminary data on clinical
impact of seviprotimut-
L, at 40 µg/dose, as measured
by RFS. The study was powered to detect a HR of 0.625,
with one-sided alpha of 0.10, and power 80%. The target
of 126 RFS events was met. The HR for RFS for the ITT
data set was 0.88 (95% CI: 0.63 to 1.23); so, these data
do not support benefit of seviprotimut-L for the whole
patient data set. However, a planned randomization stratification by stage identified a subset, representing 32% of
the study data set (stage IIB/IIC), for whom there was a
trend toward longer RFS with vaccine. Further, subgroup
analyses by age and ulceration suggest benefit for patients
under age 60 and, for the stage IIB/C stratum, those with
ulcerated primary melanomas. Analysis of impact on
OS was limited by the smaller number of events, but the
HR of 0.64 is promising. For the Stage IIB/IIC subset,
OS was longer with seviprotimut-L, with HR 0.338 (95%
CI: 0.117 to 0.975). Also, OS trended longer for patients
with stage IIB/IIC melanoma under age 60 (HR 0.216).
In the recently reported S1404 study evaluating adjuvant
pembrolizumab versus standard of care (ipilimumab or
high-
dose interferon) for patients with resected stage
III-
IV melanoma, significant improvement in RFS did
not translate to a significant impact on OS.16 Thus, the
promising early RFS and OS data for stage IIB/C patients
in the MAVIS trial are particularly promising. These data
support selection of stage IIB/C patients for the definitive final part B2 of the MAVIS phase III trial to test seviprotimut-L, with stratification by age and ulceration.
The seviprotimut-L vaccine contains soluble antigens
shed from three human melanoma cell lines, in a preparation that is readily scaled up for large patient populations. The preparation contains multiple defined antigens
shared among melanomas from many patients, including
melanocytic differentiation proteins and cancer-
testis
antigens.3 6 There is evidence that such proteins can serve
as relevant tumor-rejection antigens: vaccination with a
single shared melanocytic antigen improved progression-
free survival of patients with melanoma when added to
systemic interleukin-2 therapy in a randomized trial,17
and vaccination with a mixture of peptides from shared
Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272
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Table 3 Summary of adverse events (AEs) and protocol
discontinuation

Open access

melanocytic and cancer testis proteins has induced
durable clinical benefit in patients with advanced melanoma.18 Also, adoptive cell therapy targeting shared
cancer-testis antigens has induced durable clinical benefit
in melanoma and other cancers.19 20 A limitation of the
approach is the complexity of the antigen composition,
which limits the ability to test for immune responses that
are most relevant for tumor control. However, an advantage of the seviprotimut-L approach is that it is not limited
to a small number of peptides or proteins and does not
require selection of patients based on human leukocyte
antigen (HLA) expression.
The subgroup analyses in this report are obligatory
and inform directions for future study of this vaccine. In
stage IIB/IIC patients, there was a trend to prolonged
RFS (HR 0.666, figure 1B) and prolonged OS (HR 0.338,
figure 3B) for those who received seviprotimut-L. The
reasons for these different results based on stage are not
clear. It is true that in prior trials with PD-1 inhibitors, and
BRAF/MEK inhibition, there has been benefit across a
range of stages, for stage III and IV, as evidenced by FDA
approvals in these settings. Vaccines may have a greater
chance of benefit in earlier stages. Patients without lymph
node metastases may have more intact immune function.
Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272

It has been hypothesized that for melanoma to establish
metastases in regional nodes, the primary tumor must
first induce immune dysregulation in those nodes.21
Regardless, these findings support limiting the design
of the future part B2 trial to patients with stage IIB/IIC
melanoma, who are those for whom no systemic adjuvant
therapy is currently recommended.
Other subset findings are suggestions of benefit with
seviprotimut-L for patients younger than age 60 and for
those with ulcerated primary melanomas. In particular,
for stage IIB/IIC patients, RFS was more favorable with
seviprotimut-L for age <60 (HR 0.324, figure 1D) and
for ulcerated melanomas (HR 0.493, figure 2A). The
rationale for improved outcomes in younger patients is
supported by prior experience. Older individuals develop
immune senescence that decreases immune responsiveness,22 and they have lower immune response rates to
peptide vaccines for melanoma.23 Thus, the present study
supports evaluating the clinical impact of seviprotimut-L
in patients under age 60 in the subsequent MAVIS clinical
trial. Interestingly, PD-1 blockade has been reported to
be more effective in patients over age 60,24 suggesting the
possible benefit of combining vaccine and PD-1 blockade
specifically in older patients. The improved outcome in
7
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Figure 1 Recurrence-free survival (RFS) by arm, stage, and age. Kaplan-Meier estimates of RFS are plotted, with analysis
results in the legend and risk set and censoring accumulation below the time axis. The designation ‘(cut-off)’ indicates possible
data truncation based on designated cut-off date. (A) RFS by arm, stratified by stage, for the intent-to-treat (ITT) data set, (B)
RFS by arm and stage for the ITT data set, (C) RFS by arm and age for the ITT data set, (D) RFS by arm and age for Stage
IIB/C stratum. P values by logrank test. P value, HR and 95% CI are based on a univariate Cox regression model assuming
proportional hazards with treatment, age, and treatment×age as factors, stratified for the randomisation stratification variable of
disease stage.

Open access

patients with ulcerated primary melanomas is consistent
with prior reports of improved outcome with another
cancer vaccine and with interferon therapy for patients
with ulcerated melanomas.25 26 The finding in this trial is
also promising and may guide future trial design as well.
Several prior randomized clinical trials of cancer vaccines
have been disappointing, including the Canvaxin trials of an
allogeneic whole melanoma cell vaccine administered with
Bacillus Calmette-Guérin adjuvant.27 28 The definitive phase
III trials of that vaccine were performed in patients with stage
III and stage IV melanoma, which were negative. The lack
of an efficacy signal for stage III patients in the present trial
is consistent with that finding. Also, a randomized trial of an
autologous heat-shock protein vaccine vitespen in patients
with stage IV melanoma, also revealed no impact on overall
survival.29 Thus, the promise of cancer vaccines for melanoma remains to be realized. On the other hand, a vaccine
approach has been approved in hormone-refractory prostate
cancer,30 and a phase III trial of a peptide vaccine plus high-
dose IL-
2 significantly prolonged progression-
free survival
of patients with advanced melanoma, compared with IL-2
alone.31 The data from Part B1 of the MAVIS trial do not
meet the target impact on RFS for the whole ITT population, but promising trend to longer overall survival for the
ITT population (HR 0.64) support continued investigation
of this approach. A goal of the present study was to assess
for evidence of clinical benefit to guide a definitive Part B2
randomized phase III trial. Failure of prior trials may also
have related to the study population. The present study has
8

identified subsets who for whom there is promising preliminary evidence of efficacy of this vaccine approach, which will
thus guide the follow-up definitive trial.
Limitations of the present study include its modest
sample size and the negative findings overall for
impact on RFS. Also, the composition of the vaccine,
being derived from cell-
associated proteins, is not
conducive to laboratory correlates to assess immune
response to defined antigens. The present B1 trial did
not include analyses of immune responses; so, there
are no data on the strength of the immune responses
or their association with clinical outcome. BRAF mutation status has been associated with clinical outcome
and response to checkpoint blockade therapy, as well
as BRAF/MEK inhibitor therapy. However, during this
trial, it was not routine to assess BRAF mutation status
for resected stage II-III melanomas; yet, the arms were
well-
matched for BRAF mutation status overall in
those for whom it was known (table 1). There may be
value in stratifying also for BRAF status in subsequent
vaccine trials.
In summary, this final report of data from part B1 of
the prospective randomized multicenter MAVIS clinical trial of seviprotimut-L provides guidance useful for
design of phase III part B2 of the MAVIS clinical trial
program. Subgroup efficacy analyses identified three
groups who may benefit from seviprotimut-
L: those
with AJCC (V.7) stage IIB/C melanoma, those under
age 60, and those with ulcerated melanomas. These
Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272
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Figure 2 Recurrence-free survival (RFS) by arm, age, and ulceration for stage IIB/IIC stratum. Kaplan-Meier estimates of RFS
are plotted for stage IIB/IIC patients (A) by arm and ulceration, and (B) by arm, age and ulceration. Shown in (C) is a forest plot
for stage IIB/IIC patients as a function of age, ulceration, and both. In (D) is the Kaplan-Meier estimate for RFS for stage IIB/IIC
patients under age 60, by arm and ulceration. P values by logrank test.

Open access

data support proceeding to the definitive final part B2
of the MAVIS phase III trial to test seviprotimut-L for
stage IIB/C patients, with stratification by age and ulceration. Currently available adjuvant therapies for patients
with stage III melanoma include immune checkpoint
blockade with antibodies to CTLA-4 or PD-1, and small
molecule inhibitors of V600-mutated BRAF and MEK.
However, they are not currently approved for patients
with resected stage IIB/C melanoma. Clinical trials
currently underway evaluating PD-1 blockade for stage
IIB/IIC melanoma include Keynote 716 (NCT03553836)
and Checkmate 76K (NCT04099251). A recent press
release of Keynote 716 reports that adjuvant pembrolizumab met its primary endpoint for RFS for patients with
Slingluff CL, et al. J Immunother Cancer 2021;9:e003272. doi:10.1136/jitc-2021-003272

stage IIB/IIC melanoma32; so, the FDA is likely to review
of those data in the near future. However, in patients
without metastatic disease, the tolerance of SAEs is less
than in patients with advanced melanoma. Though PD-1
blockade is well tolerated by most patients, severe and life-
threatening toxicities can occur,33 including cardiac and
neuromuscular toxicities, which have a high mortality
risk,34 as well as diabetes35 and other endocrinopathies.36
To our knowledge, there are no phase III BRAF/MEK
inhibitor adjuvant trials in stage IIB/C melanoma. The
toxicity of dabrafenib/trametinib in the COMBI-AD adjuvant melanoma trial in Stage III patients led to SAEs in
36% of patients and permanent discontinuation of study
drug in 26% of patients.37 On the other hand, vaccination
9
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Figure 3 Survival effect modification by arm, age, and stage. Kaplan-Meier estimates of overall survival (OS) are plotted (A) for
all intent-to-treat (ITT) patients stratified by stage, by arm, (B) for all ITT patients by arm and stage, and (C) for all ITT patients by
arm and age. Shown in (D) is a forest plot for all ITT patients by stage and by age. In (E) is the Kaplan-Meier estimate for OS for
stage IIB/IIC patients by arm and age. P values by logrank test.

Open access

STATEMENT OF TRANSLATIONAL RELEVANCE
Seviprotimut-
L, a vaccine containing antigens from
human melanoma cells, is being evaluated for efficacy
in this randomized, placebo-controlled trial for patients
with AJCC v7 stage IIB-
III cutaneous melanoma after
resection. Treatment-emergent adverse events (AEs) were
similar for seviprotimut-L and placebo patients. For the
primary intent-to-treat (ITT) endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629,1.233). However,
subgroup efficacy analyses identified three groups who
may benefit from Seviprotimut-L: those with AJCC stage
IIB/IIC melanoma, those under age 60, and those with
ulcerated melanomas. These data support proceeding to
the definitive final part B2 of the MAVIS phase III trial to
test seviprotimut-L for stage IIB/C patients, with stratification by age and ulceration. In summary, seviprotimut-L is
very well tolerated. Exploratory efficacy model estimation
supports further study in stage IIB/IIC patients, especially
younger patients and those with ulcerated melanomas.
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with seviprotimut-L has an advantage of very low toxicity
without significant immune-related adverse events, and
no significant increase in toxicity over placebo. Thus, if
definitive evaluation of this vaccine therapy confirms clinical benefit in patients with stage IIB/C melanoma, the
low toxicity of this approach will be a valuable option for
these patients.
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